Arbutus Biopharma Corporation
ABUS
$4.45
$0.020.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -95.07% | 508.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -95.07% | 508.79% | |||
| Cost of Revenue | 5.09% | -38.63% | |||
| Gross Profit | -200.15% | 172.84% | |||
| SG&A Expenses | -8.53% | -42.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.05% | -40.33% | |||
| Operating Income | -533.51% | 114.68% | |||
| Income Before Tax | -406.86% | 110.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -406.86% | 110.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -406.86% | 110.29% | |||
| EBIT | -533.51% | 114.68% | |||
| EBITDA | -530.46% | 115.15% | |||
| EPS Basic | -406.06% | 110.26% | |||
| Normalized Basic EPS | -350.00% | 124.74% | |||
| EPS Diluted | -504.00% | 107.78% | |||
| Normalized Diluted EPS | -350.00% | 124.74% | |||
| Average Basic Shares Outstanding | 0.12% | 0.44% | |||
| Average Diluted Shares Outstanding | -0.32% | 0.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||